China nixes patent for Gilead HIV, hepatitis drug Viread

The move, explained BioWorld , gives China greater leverage in ongoing negotiations with drug companies around pricing.

http://www.bizjournals.com/sanfrancisco/blog/biotech/2013/08/gilead-viread-china-hiv-aids-hepatitis-b.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_sanfrancisco+%28San+Francisco+Business+Times%29